An interventional study of radiotherapy in Rectal Cancer, sponsored by University Hospital of Cologne. Not yet recruiting at 4 sites in Germany. Open to participants aged 70 Years and older. Per ClinicalTrials.gov, last updated 2026-05-01.
Sponsored by University Hospital of Cologne · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 78 studies in Rectal Neoplasms with a site in Germany — 17 open to participants now, 27 under way, 4 of them phase 3. Rectal Neoplasms · Germany.
Among the 78 studies in Rectal Neoplasms with a site in Germany, this one is the 44th largest by planned enrollment of the 62 interventional ones that give a count, is one of 3 that started in 2026, is one of 11 with no phase, reaches primary completion later than 25 of the 26 other live ones, and was the 72nd registered.
2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.
Browse Rectal Neoplasms studies →17 of the 78 studies in Rectal Neoplasms with a site in Germany are open now. Recruiting first, the newest first:
Technische Universität Dresden · Sites in Germany
Ages 18+
University Hospital Tuebingen · Sites in Germany
Ages 18+
Gruppo Oncologico del Nord-Ovest · Sites in Germany, France, Italy and 1 more country
Ages 18+
Delcath Systems Inc. · Sites in Germany, United States, Czechia and 6 more countries
Ages 18+
brenner baruch · Sites in Germany, Israel
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.
This study: 70 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
78 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 24 · Phase 3 19 · Phase 4 1
First in 1991; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is above the median of 65 across 1,754 interventional studies indexed under Rectal Neoplasms.
Median enrollment 124 across the 62 interventional studies, 596 across the 14 observational. Of the 41 that completed or were terminated, 4 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 78 have an industry lead sponsor. The 10 most frequent:
University Hospital of Cologne is the lead sponsor of 42 studies on the registry; 15 are open to participants now.
University Hospital of Cologne has 1 study filed under Rectal Neoplasms — fewer than ten, so there is no comparison to draw.
5 of the studies in Rectal Neoplasms with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06607458Delcath Systems Inc.Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease | 2026-12 |
| NCT04184973Colospan Ltd.Efficacy and Safety of the CG-100 Intraluminal Bypass Device | 2026-12-31 |
| NCT05652361Technische Universität DresdenMachine Learning-based Surgical Guidance System for Robot-assisted Rectal Surgery | 2027-01 |
| NCT05544929Novartis PharmaceuticalsA Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers | 2027-10-05 |
| NCT07407465Gruppo Oncologico del Nord-OvestUpfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer. | 2027-10-20 |
Add all 5 to your calendar (.ics) → With an account.
Among the 78 studies in Rectal Neoplasms with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
ACO/ARO/AIO-22 - External beam radiotherapy combined with endorectal high-dose-ratebrachytherapy in elderly and frail patients with rectal cancer.
A prospective multicentre trial of the German Rectal Cancer Study Group.
Epidemiological data indicate that more than 50% of patients with newly-diagnosed rectal cancer are older than 70 years, with rising numbers expected over the next decades. Albeit total mesorectal excision (TME) is considered part of the standard multimodal therapy in rectal cancer, elderly and frail rectal cancer patients are often unable to undergo radical surgery as the risk of surgical complications and postoperative mortality rises with increasing age and comorbidity. In an analysis of the Colorectal Cooperative Group UK (1988-200) in 34.194 patients with colorectal cancer, 21% of those aged over 85 years did not undergo operation, while the rates of no surgical intervention were 11% in the 75-84 years age group. Furthermore, these patients often receive no treatment at all due to frailty and concurrent diseases, resulting in local and/or systemic disease progression with associated symptoms and impaired quality of life (QoL).
Significant advances have been made in modern radiotherapy (RT), which can provide a valuable alternative non-operative treatment strategy for elderly and frail patients. Notably, to achieve clinical complete response (cCR) with RT alone, high doses are needed. Recent data from randomized trials (OPERA, MORPEUS) in young and fit patients with rectal cancer indicate that increased RT doses can be safely delivered following external beam (chemo)radiotherapy (EBRT) followed by endoluminal radiotherapeutic modalities, such as contact X-ray brachytherapy (CXB) or high-dose rate endorectal brachytherapy (HDR-BT). However, prospective studies testing this therapeutic concept in elderly and frail patients with rectal cancer remain limited. Also, despite the wide availability of brachytherapy, applicability of this concept remains largely unexplored in this challenging age subgroup in Germany.
The ACO/ARO/AIO-22 prospective trial will aim to evaluate the efficacy of EBRT in combination with endorectal HDR-BT to achieve local control (cCR) and maintain QoL in elderly and frail patients with rectal cancer that are considered unfit for radical surgery, but amenable to EBRT in combination with endorectal HDR-BT or CXB.
The ACO/ARO/AIO-22 incorporates several aspects that make this prospective study important:
Altogether, the concept of combining EBRT with endorectal HDR-BT to be tested as part of the ACO/ARO/AIO-22 prospective trial constitutes an attractive option in elderly/frail patients with rectal cancer unfit for radical surgery as it can potentially provide long-term local control of the primary tumor, prevent disease-related morbidity, prolong survival, improve QoL and even lead to cCR with complete cure in selected cases.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Prior or concurrent ≤ 3 years prior to enrolment in study (Exception: non-melanoma skin cancer or cervical carcinoma FIGO stage 0-
1), unless the patient is continuously disease-free
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will be initially treated with EBRT with 13 x 3 Gy to a total dose of 39 Gy to the primary tumor and pelvic lymph node, over a period of 2.5 weeks. Restaging with pelvic MRI and endoscopy will then be performed 6.5 weeks after completion of EBRT and prior to the first endorectal HDR-BT fraction to evaluate initial therapy response and the residual extent of the disease for target outlining. Following that, endorectal HDR-BT will be delivered with 3 x 8 Gy to a total dose of 24 Gy (dose prescription: 5 mm depth for cT1 tumors; 10 mm depth for cT2-3 tumors), with each endorectal brachytherapy application performed once weekly.
Other: radiotherapy
External beam radiotherapy and endorectal brachytherapy
Rate of Clinical Complete Response (cCR) or Near cCR at 12 Months
The primary efficacy endpoint is the proportion of patients achieving a clinical complete response (cCR) or near cCR at 12 months after the initiation of treatment, assessed through MRI and endoscopic evaluation. Quality of Life (QoL) at 12 Months Assessed using the EORTC QLQ-ELD14 questionnaire, tailored to evaluate the QoL in elderly cancer patients. The primary measure will be the change in the QoL score from baseline to 12 months.
Time frame: 12 Months
Quality of Life and Functional Outcomes
EORTC QLQ-C30 and QLQ-CR29 for general and colorectal cancer-specific QoL. Wexner-Score for anorectal function assessment. Sustained cCR at 2 Years Proportion of patients maintaining a cCR for two years post-treatment. Disease-Free Survival (DFS) at 2 Years Time from treatment initiation to recurrence or death from any cause. Cumulative Incidence of Locoregional Regrowth Frequency of locoregional tumor regrowth in patients who initially achieved cCR. Cumulative Incidence of Distant Metastases Occurrence of distant metastases within the two-year follow-up period. Overall Survival (OS) at 2 Years Duration from treatment initiation to death from any cause. Acute and Late Toxicity Evaluation Categorized based on NCI CTCAE v.5.0, focusing on adverse events related to treatment. G8 Geriatric Assessment Evaluation of frailty and health status using the G8 assessment tool, both at baseline and during follow-ups.
Time frame: 2 years
Translational/Biomarker Studies
Identification of molecular biomarkers predictive of treatment response or prognosis. Follow-Up Procedures Standardized Watch and Wait (W\&W) protocol for patients achieving cCR or near cCR at six months post-treatment.
Time frame: 6 months
Plan to share: Yes
Supporting information: Study protocol
Access criteria: ACO/ARO/AIO-22
Start is estimated for Sep 2026; primary completion for Sep 2031, 60 months later.
Of 329 non-industry interventional studies with no phase under Rectal Neoplasms, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 78. This study's planned 60 months is above that.
Counting every sponsor, half of 336 studies reached it within 51 months; a quarter within 23 and three quarters within 78.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital of Cologne